Sesha Uppalapati, MD
Endocrinology, Diabetes & Metabolism · Fort Worth, TXNPI 1154509230
Payments from drug & device makers
Across 256 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$924
- Lilly USA, LLC$741
- Boehringer Ingelheim$335
- Dexcom, Inc.$327
- Sanofi-aventis U.S. LLC$325
- Xeris Pharmaceuticals, Inc.$211
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,633100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 44 | $924 |
| Lilly USA, LLC | 55 | $741 |
| Boehringer Ingelheim | 18 | $335 |
| Dexcom, Inc. | 17 | $327 |
| Sanofi-aventis U.S. LLC | 16 | $325 |
| Xeris Pharmaceuticals, Inc. | 11 | $211 |
| Medtronic | 12 | $209 |
| AbbVie | 10 | $203 |
| Amphastar Pharmaceuticals, Inc. | 9 | $178 |
| Abbott | 8 | $138 |
| Tandem Diabetes Care, Inc. | 8 | $134 |
| Amgen | 6 | $127 |
| Insulet Corporation | 7 | $125 |
| Sequel Med Tech, LLC | 4 | $106 |
| Mannkind Corporation | 4 | $78 |
| Ascensia Diabetes Care US Inc. | 3 | $64 |
| Amneal Pharmaceuticals LLC | 3 | $53 |
| Merck | 3 | $49 |
| Corcept Therapeutics | 2 | $43 |
| IBSA Pharma Inc. | 2 | $36 |
| Recordati_rare_diseases_inc. | 2 | $32 |
| Cequr Corporation | 1 | $27 |
| Currax Pharmaceuticals LLC | 2 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Antares Pharma, Inc. | 1 | $19 |
| Acella Pharmaceuticals, LLC | 1 | $19 |
| Bayer | 1 | $18 |
| Globus Medical | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $17 |
| BETA Bionics, Inc. | 1 | $16 |
| Nevro Corp. | 1 | $13 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,645 in reported general payments places this provider in the 50th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 155 | $278,616 |
| JardianceEmpagliflozin | 189 | $269,401 |
| MounjaroTirzepatide | 73 | $114,708 |
| FarxigaDapagliflozin Propanediol | 97 | $104,389 |
| TrulicityDulaglutide | 38 | $71,422 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $67,419 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 69 | $51,919 |
| TradjentaLinagliptin | 35 | $42,878 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 11 | $42,738 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $42,105 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 20 | $39,825 |
| Humalog Kwikpen U-200Insulin Lispro | 31 | $38,058 |
| JanuviaSitagliptin Phosphate | 22 | $35,300 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 133 | $20,253 |
| Humalog Kwikpen U-100Insulin Lispro | 63 | $18,322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $335 | $312,280224 claims |
| Novo NordiskOzempic, Novolog | $924 | $283,857173 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $741 | $195,839133 claims |
| AstraZenecaFarxiga | $12 | $104,38997 claims |
| MerckJanuvia | $49 | $35,30022 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $325 | $11,91812 claims |
| AbbVieSynthroid | $203 | $4,22860 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $53 | $2,249266 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Fort Worth
- Anjanette TanFort Worth$2.5M
- Chris BajajFort Worth$785K
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.